Peapack Gladstone Financial Corp Grows Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Peapack Gladstone Financial Corp lifted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 108.0% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 293,758 shares of the medical research company's stock after buying an additional 152,539 shares during the period. Peapack Gladstone Financial Corp's holdings in Edwards Lifesciences were worth $19,385,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of EW. FSA Wealth Management LLC bought a new stake in Edwards Lifesciences during the 3rd quarter worth $30,000. Prospera Private Wealth LLC bought a new stake in Edwards Lifesciences during the 3rd quarter worth $32,000. Avior Wealth Management LLC grew its position in Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock worth $35,000 after acquiring an additional 308 shares during the last quarter. Peoples Bank KS bought a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at about $40,000. Finally, JFS Wealth Advisors LLC grew its position in shares of Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company's stock valued at $46,000 after buying an additional 166 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on EW shares. Citigroup upped their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the company a "buy" rating in a research report on Wednesday. Evercore ISI reduced their price target on Edwards Lifesciences from $76.00 to $70.00 and set an "in-line" rating on the stock in a research report on Tuesday, October 1st. Royal Bank of Canada upped their price target on Edwards Lifesciences from $80.00 to $85.00 and gave the company an "outperform" rating in a research report on Thursday, December 5th. JPMorgan Chase & Co. upped their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the company a "neutral" rating in a research report on Friday, October 25th. Finally, Robert W. Baird reduced their price target on Edwards Lifesciences from $73.00 to $68.00 and set a "neutral" rating on the stock in a research report on Friday, October 25th. Seventeen investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $78.65.

Edwards Lifesciences Stock Performance

NYSE EW traded down $0.65 on Friday, hitting $73.32. 2,969,659 shares of the stock traded hands, compared to its average volume of 4,642,550. The business's fifty day moving average is $69.26 and its two-hundred day moving average is $74.19. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The firm has a market capitalization of $43.24 billion, a price-to-earnings ratio of 10.67, a PEG ratio of 3.63 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same period in the prior year, the company earned $0.59 earnings per share. Edwards Lifesciences's revenue was up 8.9% compared to the same quarter last year. As a group, equities analysts anticipate that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm's stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the firm's stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the sale, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. The trade was a 11.18 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 35,000 shares of company stock valued at $2,323,150 over the last three months. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.